Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment

CA Febres-Aldana, R Fanaroff, M Offin… - Annual Review of …, 2024 - annualreviews.org
Diffuse pleural mesothelioma (DPM) is a highly aggressive malignant neoplasm arising from
the mesothelial cells lining the pleural surfaces. While DPM is a well-recognized disease …

[HTML][HTML] The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication …

MT Congedo, EC West, J Evangelista… - Journal of Thoracic …, 2024 - ncbi.nlm.nih.gov
The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and
germline variants, clinicopathological features and implication in practical medical/surgical …

ATG5 as biomarker for early detection of malignant mesothelioma

M Tomasetti, F Monaco, O Strogovets, L Volpini… - BMC Research …, 2023 - Springer
Objectives Malignant pleural mesothelioma (MPM) is an aggressive disease with grim
prognosis due to lack of effective treatment options. Disease prediction in association with …

miR 31-3p Has the Highest Expression in Cesarean Scar Endometriosis

M Szubert, A Nowak-Glück… - International Journal of …, 2022 - mdpi.com
Micro-RNAs expression can vary between different forms of endometriosis, but data on
miRNA expression in cesarean scar endometriosis is lacking. The present study is …

Microbiomes, epigenomics, immune response, and splicing signatures interplay: Potential use of combination of regulatory pathways as targets for malignant …

BP Setlai, ZL Mkhize-Kwitshana, R Mehrotra… - International Journal of …, 2022 - mdpi.com
Malignant mesotheliomas (MM) are hard to treat malignancies with poor prognosis and high
mortality rates. This cancer is highly misdiagnosed in Sub-Saharan African countries …

Miglioramento delle strategie di trattamento dei Tumori Epiteliali Timici (TETs)

G Ricci - 2022 - iris.univpm.it
Background: Thymic epithelial tumors (TETs) are rare and extremely heterogeneous
malignances (the annual global incidence varies from 1.3 to 3.2 per milion persons and …